You are here

An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Chubu Rosai Hospital
Nagoya, Aichi, Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Spinal Cord Diseases, Spinal Cord Injuries, Neuralgia, Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Inclusion criteria for subjects to be shifted from Study A0081107

- Subjects who completed the 18-week study period in Study A0081107 conducted for
chronic neuropathic pain after spinal cord injury;

- Subjects who completed assessments of all efficacy endpoints until the end of the
treatment phase of the preceding Study A0081107 (V7);

Inclusion criteria for subjects to be new participants in this study

- Subjects with central neuropathic pain after stroke or multiple sclerosis;

- At least 6 months have passed after the onset of central neuropathic pain;

- Pain VAS at least 40mm in Visit 1 and Visit 2;

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Creatinine clearance

- Platelet count count

- Subjects who are expected to require surgery during the trial;

NCT01202227
Pfizer
Completed
An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis, Vaso-occlusive Crisis
NCT02433158
All Genders
6+
Years
Multiple Sites
Moderate-severe Pain
NCT02101554
All Genders
7+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now